Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer

Immune checkpoint inhibitor-related pneumonitis (ICI-P) during cancer treatment is rarely observed (<5%). ICI-P is more often observed in patients with nonsmall cell lung cancer (NSCLC) than in those with other cancers. Likewise, it is more common in those receiving programmed cell death (PD)-1/P...

Descripción completa

Detalles Bibliográficos
Autores principales: Cadranel, Jacques, Canellas, Anthony, Matton, Lise, Darrason, Marie, Parrot, Antoine, Naccache, Jean-Marc, Lavolé, Armelle, Ruppert, Anne-Marie, Fallet, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2019
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488121/
https://www.ncbi.nlm.nih.gov/pubmed/31597674
http://dx.doi.org/10.1183/16000617.0058-2019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488121/
https://www.ncbi.nlm.nih.gov/pubmed/31597674
http://dx.doi.org/10.1183/16000617.0058-2019

Ejemplares similares